Psychedelic Access in Europe: What Changed — September 2026

<!-- Monthly regulatory monitor — issue 1 (September 2026), covering roughly 5 July – 3 September 2026. Format is built for monthly reissue: update the frontmatter month, move the previous window's items into the archive section at the bottom, and refresh "Last verified". Every dated item below was verified against its primary source on 2026-09-03 (KBV press release, CTIS records via data/ctis_trials.json + live check, Czech guideline portal, UK government response and written answer, BAG-commissioned programme report). -->

Regulatory access to psychedelic and ketamine-family treatment in Europe changes in small, dated steps — a billing decision here, a trial approval there — that rarely make headlines but determine what patients can actually get. This page is a monthly monitor of those steps: what changed in the last ~60 days, country by country, each item with a date and a primary source. It is a companion to our standing reference pages — is ketamine therapy legal in Europe?, where in Europe you can get psychedelic therapy and the statistics page — which describe the stable picture; this one records the movement.

This issue: September 2026 (issue 1), covering roughly 5 July – 3 September 2026. Last verified: 3 September 2026.

Germany

• 13 August 2026 — Esketamine observation billing stays restricted to psychiatric specialties. The KBV (National Association of Statutory Health Insurance Physicians) proposed, in the Bewertungsausschuss, extending the right to bill for the mandatory post-dose observation of intranasal esketamine (Spravato) — currently billing code GOP 01549, introduced October 2023 — to GPs, neurologists and other specialist groups, so patients could be monitored closer to home. The insurer side rejected the draft outright; the KBV board publicly criticised the decision as "a lost chance to improve care for these severely ill patients". Practical effect: supervised esketamine administration in Germany remains billable only in a narrow set of psychiatric specialties, which is a real capacity ceiling given the multiple-sessions-per-week induction schedule. Source: KBV press release, 13.08.2026; background on the code: KV Hessen — Spravato observation billing.
• Context, unchanged: esketamine remains reimbursed with a G-BA "considerable added benefit" rating since 2023; Germany's two-site psilocybin compassionate-use programme continues. See the Germany access guide.

Netherlands

• 26 August 2026 — MDMA trial approved. CTIS records show a national decision for a Phase II (therapeutic exploratory) trial of MDMA for post-traumatic stress disorder, sponsored by Stichting Amsterdam UMC (CT no. 2024-515184-65-01), with two Dutch sites. For a country whose state commission urged movement on therapeutic MDMA while the cabinet kept to the regular medicines route, investigator-led trials are currently where that movement happens. Source: EU Clinical Trials Register (CTIS), CT 2024-515184-65-01.
• Context, unchanged: psilocybin and MDMA remain clinical-research-only in Dutch healthcare; esketamine is reimbursed from the basic package under treatment-resistant depression conditions. See the Netherlands access guide.

Denmark

• 1 August 2026 — Psilocybin for anorexia nervosa approved. CTIS shows a Danish decision for a Phase II psilocybin trial in anorexia nervosa, sponsored by Slagelse Hospital (CT no. 2025-524939-39-02) — a notable indication choice, since anorexia is among the deadliest psychiatric conditions and has no approved pharmacotherapy. Source: EU Clinical Trials Register (CTIS), CT 2025-524939-39-02.
• Context, unchanged: Denmark's route to psychedelic treatment remains research participation; ketamine/esketamine follow the hospital system. See the Denmark access guide.

Italy

• 14 August 2026 — Psilocybin + trazodone dose-finding study approved. CTIS shows an Italian decision for a Phase IIa open-label study evaluating whether trazodone can attenuate the consciousness-altering effects of psilocybin in treatment-resistant depression, sponsored by the University of Chieti (CT no. 2025-523346-27-00), four Italian sites. If the attenuation concept holds, it speaks to a live scientific question — whether the subjective experience is required for the antidepressant effect. Source: EU Clinical Trials Register (CTIS), CT 2025-523346-27-00.

Czechia

• Status, September 2026 — the EU's first psilocybin framework is live but not yet treating. The Czech framework permitting psilocybin-assisted treatment in healthcare facilities — the first of its kind in the EU — has been in force since 1 January 2026, limited to defined severe-depression indications under certified psychiatric teams. The Czech Psychiatric Society's 2026 recommended-practice guideline for psilocybin treatment is published, and early providers publicly expect first treatments in the second half of 2026, with initial capacity of a few dozen patients a year, mainly Prague and Brno. Sources: Czech Psychiatric Society, Doporučené postupy 2026 — psilocybin treatment; Zdravotnický deník interview on the 2026 rollout.

United Kingdom

• Status, September 2026 — pilot still in design, no rescheduling. No new public decision fell in this window. The standing position: on 16 July 2025 the government formally accepted, in principle, the ACMD's recommendation to let universities and NHS clinical-trial sites conduct Schedule 1 research (including psilocybin) without a separate controlled-drugs licence, to be tested through a pilot scheme; a written parliamentary answer of 27 October 2025 confirmed the pilot was being designed. Psilocybin itself remains Class A, Schedule 1, and there is no UK medical psilocybin access route. Sources: UK Parliament written answer 85461, 27.10.2025; Parliamentary POST briefing on psychedelic-assisted therapy policy.

Switzerland

• Status, September 2026 — the limited-medical-use programme continues; no fresh decision this window. The most recent published programme data remain those of the 2025 BAG-commissioned evaluation: roughly 700 FOPH exceptional-use permits in 2024 (LSD, MDMA and psilocybin under Article 8(5) NarcA) and around 100 authorised treating physicians. We found no newer official figures in this window; when BAG publishes 2025/2026 numbers, they will appear here. Sources: BAG — limited medical use of prohibited narcotics; Meier et al. 2025 — history and characteristics of the Swiss limited medical use programme.

Austria

• Nothing verified this window. We found no dated regulatory or access change in psychedelic or ketamine-family medicine in Austria between early July and early September 2026 that we could trace to a primary source. An empty section is information too: absence of movement, honestly recorded.

What we deliberately leave out

This tracker covers psychedelic and ketamine-family medicine only. Cannabis regulation — including Spain's Royal Decree 903/2025 on medical cannabis — moves on its own track and is out of scope here, even where the same agencies (SÚKL, BAG) administer both. Trials data comes from the EU's CTIS register via our scheduled refresh plus a manual check at publication; how to read trial phases and what participation involves is in our clinical trials guide.

How this tracker works

New issue monthly; this September 2026 edition is issue 1. Each item carries the decision date, what changed in practical terms, and a primary source — regulator, register or official press release, never news aggregation alone. Items from previous windows move to an archive section as issues accumulate. If you spot a dated, sourceable change we missed, write to hello@psyaccess.health.

How to cite this page

Cite as: PsyAccess, "Psychedelic Access in Europe: What Changed — September 2026", psyaccess.health, last verified 3 September 2026, https://psyaccess.health/guides/psychedelic-access-updates/. Each dated item carries its primary source above; you are welcome to reuse individual items with attribution.

This page tracks regulation and availability; it is not medical advice, and inclusion of a treatment or trial is not a recommendation. For whether any route is open to you, start with the eligibility check or your clinician.